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A patient with a heterozygous variant of Creutzfeldt-Jakob 
disease (CJD) with a methionine/valine genotype at codon 
129 of the prion protein gene was recently reported. Us-
ing an ultrasensitive and specific protein misfolding cyclic 
amplification–based assay for detecting variant CJD prions 
in cerebrospinal fluid, we discriminated this heterozygous 
case of variant CJD from cases of sporadic CJD.
Variant Creutzfeldt-Jakob disease (vCJD) is a neu-rodegenerative infectious disease caused by trans-
mission of a cattle prion disease (bovine spongiform 
encephalopathy) to humans (1). Most vCJD cases have 
occurred in the United Kingdom, where an estimated 1 
in 2,000 persons is potentially asymptomatically infected, 
although there is some uncertainty about interpretation 
of detection of abnormal prion protein (PrPTSE) in appen-




Until recently, all clinical cases of vCJD for which the 
prion protein gene has been analyzed have been shown to be 
methionine homozygous at codon 129, a genotype present 
in almost 40% of Caucasian populations. The report of the 
first definite heterozygous methionine/valine vCJD patient 
who died in 2016 (3) underlined previous concern about a 
possible second wave of vCJD cases (4). The clinical fea-
tures of this patient were more similar to those of patients 
with sporadic CJD (sCJD) than to those with vCJD. This pa-
tient had met the agreed surveillance diagnostic criteria for 
probable sCJD (5). However, vCJD was diagnosed during 
an autopsy; florid plaques were observed by histologic ex-
amination of the brain and peripheral detection of PrPTSE 
in lymphoid tissues. Western blot analysis of brain tissue 
confirmed a type 2B molecular profile of PrPTSE, which is 
characteristic for vCJD.
A diagnostic test to identify methionine/valine hetero-
zygous vCJD cases is urgently needed to enable discrimi-
nation between heterozygous vCJD and sCJD and in view 
of the potential reservoir of methionine/valine heterozy-
gous asymptomatic vCJD carriers in the blood donor popu-
lation. We developed a highly sensitive and specific assay 
that accurately detects vCJD prions in blood even before 
the occurrence of clinical signs (6). We adapted this assay, 
which was based on protein misfolding cyclic amplifica-
tion (PMCA) (7), for specific detection of vCJD in cerebro-
spinal fluid (CSF) and confirmed the ability of this assay 
to differentiate patients with atypical heterozygous vCJD 
from patients with sCJD.
The Study
We blindly analyzed 98 CSF samples provided by the Na-
tional CJD Research and Surveillance Unit (Edinburgh, 
Scotland, UK) and the Centre Hospitalier Universitaire de 
Montpellier (Montpellier, France) after obtaining appropri-
ate consent. Clinicians distributed CSF samples into blind-
ed panels from the United Kingdom and France; 41 from 
patients with vCJD; 23 from patients with sCJD; 1 from a 
patient with genetic CJD; and 33 from patients with non-
CJD, including samples from patients with Alzheimer’s 
disease and patients with nonneurodegenerative diseases.
CSF samples were thawed at room temperature and 
used directly in PMCA. We performed PMCA amplifica-
tion by using brains from humanized transgenic mice as 
substrate for normal prion protein. After successive rounds 
of 160 cycles of PMCA for 15 min and sonication for 20 
s, we detected PrPTSE by using Western blot after digestion 
with proteinase K (6).
Of the 98 CSF samples analyzed, our assay identified 
40 of 41 cases of clinical vCJD, including the methionine/
valine heterozygous patient, thus showing a diagnostic 
sensitivity of 97.6% (95% CI 87.1%–99.9%) (Table). One 
CSF sample from a probable case of vCJD showed a nega-
tive result. After decoding by clinicians, we retested this 
sample in duplicate; it showed a positive result.
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Our assay also showed high analytical specificity; 0 
of 57 potentially cross-reacting CSF specimens from pa-
tients with sCJD, gCJD, Alzheimer’s disease, and other 
nonneurodegenerative diseases showed a positive result 
(specificity 100% [95% CI 93.7%–100%]) (Table). The 
case-patient with methionine/valine heterozygous vCJD 
was specifically discriminated from the 12 methionine/
valine heterozygous neuropathologically confirmed sCJD 
case-patients tested.
We then compared by using Western blot the PrPTSE 
molecular signature obtained for the clinical vCJD am-
plified samples from classical methionine homozygous 
cases and the new methionine/valine heterozygous vCJD 
case with that of the reference brain sample from a patient 
with vCJD (Figure). As expected, the profile obtained af-
ter PMCA amplification of the CSF from the methionine/
valine heterozygous vCJD patient was similar to those 
obtained for methionine homozygous vCJD patients. The 
characteristic type 2 mobility and clear predominance of 
the diglycosylated isoform was obtained for all vCJD pa-
tients before or after amplification.
Conclusions
We report a specific detection method that enables clini-
cal diagnosis of a heterozygous methionine/valine hetero-
zygous vCJD patient. This patient was the first definite 
heterozygous patient described since the start of the vCJD 
epidemic in the United Kingdom in 1996 (3). Clinical di-
agnosis was difficult because clinical signs and symptoms, 
particularly cerebral appearance by magnetic resonance 
imaging, were suggestive of sCJD (3). The vCJD blood test 
(direct detection assay) developed by the Medical Research 
Council Prion Unit (London, UK) (8) showed a negative 
result for this case-patient. We found characteristic vCJD 
prion protein amplification in the CSF, which led to a spe-
cific diagnosis of vCJD because sCJD samples did not show 
positive results by PMCA. This result also demonstrates 
the possibility of amplifying methionine/valine heterozy-
gous vCJD prion protein by PMCA with a substrate from 
humanized transgenic mice that overexpress homozygous 
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Table. Analysis of CSF samples from patients with CJD and controls by PMCA* 
Diagnosis 
No. patients with positive detection of PrPTSE in 
CSF and codon 129 genotype/no. tested 
Analytical performance, % (95% CI) Total MM MV VV 
Clinical CJD      
 Variant CJD 40/41† 37/38 1/1 NA Diagnostic sensitivity 97.6 (87.1–99.9) 
  Definite 29/29 28/28 1/1 NA  
  Probable 10/11 8/9 NA NA  
  Possible 1/1 1/1 NA NA  
 Sporadic CJD 0/23† 0/7 0/12 0/3 Analytic specificity 100 (93.7–100) 
  Definite 0/14 0/2‡ 0/10 0/1‡  
  Probable 0/9 0/5 0/2 0/2  
 Genetic CJD 0/1 0/1 NA NA Analytic specificity 100 (93.7–100) 
Non-CJD     Analytic specificity 100 (93.7–100) 
 Alzheimer’s disease 0/12 ND ND ND  
 Other nonneurodegenerative diseases 0/21 ND ND ND  
*CJD, Creutzfeldt-Jakob disease; CSF, cerebrospinal fluid; MM, methionine homozygous; MV, methionine/valine heterozygous; NA, not available; ND, not 
determined; PMCA, protein misfolding cyclic amplification; PrPTSE, abnormal prion protein; VV, valine homozygous. 
†Genotyping of the prion protein gene at codon 129 was not conducted for 2 patients with variant CJD and 1 patient with sporadic CJD. 
‡The protease-resistant protein subtype was available for 3 patients with definite sporadic CJD and showed an equal distribution of MM1, MM2a,  
and VV2a. 
 
Figure. Western blot analysis of vCJD prions obtained after 
amplification by protein misfolding cyclic amplification (PMCA) of 
cerebrospinal fluid (CSF) from 2 patients with vCJD (MM and MV) 
and 3 control patients and a crude reference brain homogenate 
from a vCJD patient (National Institute for Biological Standards 
and Control [Ridge, UK] no. NHBY0/0003). Abnormal prion protein 
patterns were assessed by using antibody 3F4 after digestion of 
samples with proteinase K. A total of 20 µL of each sample was 
subjected to electrophoresis on a 12% polyacrylamide gel. Lane 
NBH, negative control brain homogenate from a person without 
CJD and no digestion with proteinase K (National Institute for 
Biological Standards and Control no. NHBZ0/0005); lane –3na, 
Western blot control (10–3 dilution of vCJD reference brain sample 
without amplification); lane TP, positive control for amplification (10–6 
dilution of vCJD reference brain sample after 1 round of PMCA); 
lane vCJD-MM, CSF from a patient with MM vCJD after 3 rounds 
of PMCA; lane vCJD-MV, CSF from a patient with MV vCJD after 
3 rounds of PMCA; lane sCJD-MV, CSF from a patient with MV 
sCJD after 5 rounds of PMCA; lane gCJD, CSF from a patient with 
gCJD after 5 rounds of PMCA; lane AD, CSF from a patient with 
Alzheimer’s disease after 5 rounds of PMCA. CJD, Creutzfeldt-
Jakob disease; gCJD, genetic CJD; MM, methionine homozygous; 
MV, methionine/valine heterozygous; Rd, round (1 round indicates 
80 cycles of PMCA); sCJD, sporadic CJD; vCJD, variant CJD.
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methionine prion protein (9). However, PMCA analysis 
should be performed in a Biosafety Level 3 laboratory and 
requires highly experienced personnel.
Iatrogenic transmission of vCJD by blood transfusion 
has been documented in 3 recipients of nonleukodepleted 
erythrocyte concentrates from blood donors during devel-
opment of disease (10). One additional probable case of 
vCJD transmission by blood transfusion was identified 
during an autopsy of a methionine/valine heterozygous pa-
tient who died from a nonneurologic disorder and in whom 
vCJD prion protein was detected in the spleen (11). The 
presence of infectivity in blood of the definite methionine/
valine heterozygous vCJD patient involved in our study is 
uncertain and requires further investigation.
From a clinical point of view, prion amplification tech-
nologies, such as PMCA and real-time quaking-induced 
conversion (RT-QuIC), have already shown their sensitive 
detection of disease-related prion protein in biologic flu-
ids (6,12–14). Independent studies have shown that detec-
tion of prion protein seeding activity in CSF by RT-QuIC 
might have a specificity of 99%–100% for diagnosis of 
sCJD (13,15). Application of RT-QuIC and PMCA for CSF 
samples might represent a suitable strategy for premortem 
discrimination between sCJD and vCJD including methio-
nine/valine heterozygous case-patients, particularly for cases 
with a heterozygous codon 129 genotype in which clinical 
distinction between sCJD and vCJD is problematic.
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